Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|122|17|2654-2662

ISSN： 0008-543x

Source： CANCER, Vol.122, Iss.17, 2016-09, pp. : 2654-2662

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-HER2 Therapy in Elderly Breast Cancer Patients

By  

Reviews on Recent Clinical Trials, Vol. 9, Iss. 4, 2014-01 ,pp. : 263-266

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy in HER2-Positive Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 295-302

Karger

Access to resources Recommend Favorite

Targeted Therapy of HER2-Negative Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 3, 2016-02 ,pp. : 118-121

Karger

Access to resources Recommend Favorite

Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 32-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies

By  

Oncology, Vol. 78, Iss. 2, 2010-04 ,pp. : 141-149

Karger

Access to resources Recommend Favorite